Clinical Pipelines-3

Regenerative Medicine Products

REPROCELL's clinical pipelines for spinocerebellar degeneration, ALS, and solid cancers

Clinical Pipelines currently under development

REPROCELL is advancing the research and development of a wide range of therapies using stem cells and immune cells, with the aim of realizing next‑generation medicine tailored to each individual patient.

Our current lineup includes the adipose‑derived mesenchymal stem cell product Stemchymal® for spinocerebellar degeneration; iPS cell‑derived neural glial progenitor cells (iGRP) targeting central nervous system disorders such as ALS and TM; and, TIL therapy and Glypican‑1 CAR‑T therapy as cell‑based immunotherapies for cancer.

Through the development of these therapies, REPROCELL is striving to bring new treatment options into practical use as quickly as possible.

R&D
Pre-clinical
Clinical Trial
Approval
Stemchymal®

Stemchymal® — Spinocerebellar Degeneration (SCA)

 
iGRP

iGRP — Amyotrophic Lateral Sclerosis (ALS) and Transverse Myelitis (TM)

 
TIL

TIL — Cervical Cancer

 
GPC1 CAR-T

GPC1 CAR-T — Squamous cell carcinoma, including esophageal cancer

 

Clinical pipelines - Stemchymal therapy packs

For Patients with Spinocerebellar Degeneration

Stemchymal®

Stemchymal is a regenerative medicine product developed by Steminent Biotherapeutics (Taiwan).

We have completed Phase-II clinical trial in Japan, and are preparing for the approval application to deliver it to the patients as quickly as possible.

Stemchymal therapy

Clinical pipelines - iGRP - neural cells

For patients with ALS/TM

iPS cell-derived neural glial cells (iGRP)

For central nerve system diseases such as Amyotrophic Lateral Sclerosis (ALS) and Transverse Myelitis (TM), we are developing neural glial progenitor cells (iGRP) from iPS cells. We are under preclinical tests and, in parallel, preparing for clinical trials.

iGRP therapy

Clinical pipelines - TIL - cervical cancer

For patients with Cervical Cancer

Tumor Infiltrating Lymphocyte (TIL)

TIL therapy is a type of adoptive immunotherapy in which tumor-infiltrating lymphocytes (TILs) from the patient’s own cancer tissue are collected, cultured in large quantities ex vivo, and then reintroduced into the patient. TIL therapy has previously shown efficacy against advanced malignant melanoma. We are proceeding a clinical trial of TIL for cervical cancer.

TIL therapy

GPC1 CART

For patients with solid tumors such as esophageal cancer

Anti-Glypican 1 Chimeric Antigen Receptor T-cell Therapy (GPC1 CAR-T)

GPC1-specific CAR-T therapy involves extracting the patient's own T cells (immune cells), genetically modifying them to recognize solid tumors, and then re-infusing them into the patient for treatment. While conventional CAR-T therapy is effective for hematologic cancers, its efficacy against solid tumors has been limited. This therapy targets GPC1 specifically expressed on various solid tumors including esophageal, lung squamous, and pancreatic cancers.

GPC1 CAR-T therapy